Home Report Catalogue Pharmaceuticals APAC Shingles Vaccines Market Analysis
Pharmaceuticals APAC

APAC Shingles Vaccines Market Analysis, 2024–2034

APAC Shingles Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $899.3 Mn Estimated value
Estimate 2025 $976.7 Mn 19% of the global market
Projected 2034 $2.05 Bn 110.1% Adds $1.08 Bn over 9 forecast years
CAGR 2025–2034 8.6% Faster than 43% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 18.96% of the global market.
  • Among regions, the largest is North America at $2.66 Bn.
  • Fastest growing: APAC (this report) at 8.6% a year.
  • APAC ranks 3rd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.08 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Shingles Vaccines Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $899.3 Mn — —
2025 (base) $976.7 Mn +$77.3 Mn —
2026 (forecast) $1.06 Bn +$84.0 Mn +8.6%
2027 (forecast) $1.15 Bn +$91.2 Mn +17.9%
2028 (forecast) $1.25 Bn +$99.1 Mn +28.1%
2029 (forecast) $1.36 Bn +$107.6 Mn +39.1%
2030 (forecast) $1.48 Bn +$116.8 Mn +51.1%
2031 (forecast) $1.60 Bn +$126.9 Mn +64.1%
2032 (forecast) $1.74 Bn +$137.8 Mn +78.2%
2033 (forecast) $1.89 Bn +$149.6 Mn +93.5%
2034 (forecast) $2.05 Bn +$162.5 Mn +110.1%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $5.15 Bn
  2. North America $2.66 Bn
  3. US $1.98 Bn
  4. Europe $1.00 Bn
  5. APAC (this report) $976.7 Mn
  6. China $468.3 Mn
  7. Canada $395.1 Mn
  8. Japan $351.7 Mn
  9. Latin America $261.4 Mn
  10. Middle East $210.1 Mn
  11. Germany $182.6 Mn
  12. Italy $140.2 Mn
  13. Brazil $135.4 Mn
  14. France $120.7 Mn
  15. UK $117.4 Mn
  16. Saudi Arabia $100.2 Mn
  17. Ecuador $96.8 Mn
  18. India $100.6 Mn
  19. Africa $90.2 Mn
  20. Spain $86.6 Mn
  21. Mexico $70.3 Mn
  22. Australia $66.6 Mn
  23. New Zealand $57.6 Mn
  24. Russia $53.6 Mn
  25. South Africa $30.2 Mn
  26. UAE $25.7 Mn
  27. Egypt $16.3 Mn
  28. Philippines $10.2 Mn
  29. Hong Kong $9.4 Mn
  30. Malaysia $9.1 Mn
  31. Singapore $6.7 Mn
  32. Thailand $6.0 Mn
  33. Kenya $3.1 Mn

The APAC Shingles Vaccines Market Analysis Executive Summary

Shingles vaccines prevent herpes zoster, a painful rash caused when the chickenpox virus wakes up again, mostly in older adults.

Key segments of the shingles Vaccines market include type (Recombinant Vaccines and Live Attenuated Vaccines) and age (50-64 Years, 65 Years and Above and Immunocompromised Adults).

APAC Shingles Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the shingles Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the shingles Vaccines market.

Competitive Landscape for Shingles Vaccines Market in APAC

The shingles Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Shingles Vaccines Market in APAC

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for shingles Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Shingles Vaccines in APAC? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Bone and Joint Health: Supplements for an Ageing Population1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence… Eye Health Supplements: Screens, Ageing and Vision2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a… Collagen Supplements: Skin, Joints and Real EvidenceCollagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in APAC

See all
Same topic, other categories

Related on vaccines and geriatric

See the topic